Category: Blog

Blog

Michael Rae and Dr. Robert Rodgers discuss Parkinson’s and aging

SENS Research Foundation’s science writer Michael Rae was interviewed on the Parkinson’s Recovery radio program on “The coming rejuvenation biotechnology revolution for Parkinson’s disease.” In it, they discussed how the cellular and molecular damage of aging most closely involved in Parkinson’s can be removed, replaced, or repaired using rejuvenation biotechnologies, and research underway to make it happen.Read more and listen to the interview to learn how a “damage-repair” approach can prevent, arrest, and eventually consign Parkinson’s to history.

Read More »
Featured

SENS Research Foundation & Underdog Pharmaceuticals jointly awarded $252,000 NIA research grant

The National Institute on Aging (NIA) division of the National Institutes of Health (NIH) has awarded a grant to advance research on Engineered Cyclodextrins targeting toxic oxidized cholesterol to eradicate atherosclerosis — the cause of most heart attacks and strokes.

Former SRF V.P. of Research and current Underdog Co-founder Matthew O’Connor, Ph.D. and current SRF V.P. of Research Alexandra Stolzing, Ph.D., are the Principal Investigators.

Read More »
Featured

British Daily Mirror featured an interview with SENS Research Foundation’s Science Writer Michael Rae about the world’s richest men taking on the longevity challenge

As part of the widespread media coverage of the launch of Altos Labs and the rising tide of investment into rejuvenation biotechnology, a recent article in a British daily featured an interview with SENS Research Foundation’s Science Writer Michael Rae on Altos Labs, cellular reprogramming, and its place within the SENS platform of rejuvenation biotechnologies and the push toward a future of indefinite medical maintenance of healthy, youthful life.

Read More »
Featured

Longevity Science Foundation’s $1 billion, 10 year distribution shows shift in attitudes since SRF inception

SRF is elated at the announcement in Longevity Technology of a fund that will distribute more than $1 billion over a ten year period specifically “to research, institutions and projects advancing healthy human longevity and extending the healthy human lifespan to more than 120 years.”

Few may remember the environment in which SRF began, in which interest in longevity research and significant extension of human life was far outside the mainstream. This financial commitment is another hard-fought victory in shifting attitudes towards fighting aging.

Read More »

Hyperbolic Hyperbaric “Age Reversal”

Lower-quality, clickbait-hungry media outlets love sensationalist claims, but one does expect better from the public relations department of an internationally-respected research university. And it was an easy jump from the already-overstated “In First, Aging Stopped in Humans” and “treatments can reverse two processes associated with aging and its illnesses” to saying that a treatment “can reverse

Read More »

Parabiosis: the Dilution Solution?

In heterochronic parabiosis, joining the circulatory systems of young and old mice causes the older animal to recover some features of youth. The effect has been widely assumed to be driven by pro-youth factors in younger blood, but an alternative hypothesis is possible: that the procedure is instead diluting pro-aging factors in the older partner.

Read More »

Double Your Impact

If you’ve invested in a donor-advised fund (DAF), you know that a key advantage of these funds is that they let you put charitable money aside when you have a jump in earnings, and watch for the best time and project to invest your money. We’re here (along with special guest Herbie Hancock) to tell you that now is that time!

Read More »

COVID-19 and Aging

Why is the novel coronavirus so deadly to the elderly? We outline some of the ways in which aging is relevant to diseases like COVID-19 – and how our research may help render future viruses far less dangerous.

Read More »

Smart Bombs Against Senescent Cells

Summary: A new nanotechnology enables the selective targeting of senescent cells; in mice, it dramatically improves an age-related lung disease, and makes cancer chemotherapy safer and more effective. Now the scientists behind it have a startup and are headed toward human testing.

Read More »

Pathway To New Therapies

Article by Michael Rae about recent and forthcoming regulatory reforms required to support the testing of new therapies for Alzheimer’s and other age-related diseases.

Read More »

Human Trials of Two New Rejuvenation Biotechnologies Targeting Alpha-Synuclein

Alpha-synuclein aggregates are a key form of aging damage in the brain, linked to a spectrum of symptoms in Parkinson’s disease beyond the classic motor symptoms. The first amyloSENS-style immunotherapy to clear this pathology out of the brain was advanced into clinical trials by Austrian biotech firm AFFiRiS AG. Now two more such therapies have entered human testing. Although the trials are in their earliest stages, they bring the hope that this rejuvenation biotechnology will begin preventing and reversing Parkinson’s disease and less specific disorders of aging soon.

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can

SENS Research Foundation Audience Survey

And follow the link at the end to WIN!: